vs
Side-by-side financial comparison of Sanara MedTech Inc. (SMTI) and UNITY BANCORP INC (UNTY). Click either name above to swap in a different company.
UNITY BANCORP INC is the larger business by last-quarter revenue ($35.3M vs $27.5M, roughly 1.3× Sanara MedTech Inc.). UNITY BANCORP INC runs the higher net margin — 43.9% vs -5.9%, a 49.7% gap on every dollar of revenue. On growth, UNITY BANCORP INC posted the faster year-over-year revenue change (24.2% vs 4.6%). UNITY BANCORP INC produced more free cash flow last quarter ($44.3M vs $3.9M). Over the past eight quarters, Sanara MedTech Inc.'s revenue compounded faster (21.8% CAGR vs 17.5%).
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
Unity Bancorp Inc is a New Jersey-headquartered financial holding company operating Unity Bank. It offers a full range of commercial and retail banking services including business loans, deposit products, mortgage services, and personal banking solutions, primarily serving small and medium-sized enterprises and individual consumers across local communities in New Jersey and eastern Pennsylvania.
SMTI vs UNTY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.5M | $35.3M |
| Net Profit | $-1.6M | $15.5M |
| Gross Margin | 93.2% | — |
| Operating Margin | 23.5% | 55.8% |
| Net Margin | -5.9% | 43.9% |
| Revenue YoY | 4.6% | 24.2% |
| Net Profit YoY | 5.3% | 34.5% |
| EPS (diluted) | $-0.32 | $1.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $27.5M | $35.3M | ||
| Q3 25 | $26.3M | $32.8M | ||
| Q2 25 | $25.8M | $34.4M | ||
| Q1 25 | $23.4M | $29.4M | ||
| Q4 24 | $26.3M | $28.4M | ||
| Q3 24 | $21.7M | $27.7M | ||
| Q2 24 | $20.2M | $25.5M | ||
| Q1 24 | $18.5M | $25.6M |
| Q4 25 | $-1.6M | $15.5M | ||
| Q3 25 | $-30.4M | $14.4M | ||
| Q2 25 | $-2.0M | $16.5M | ||
| Q1 25 | $-3.5M | $11.6M | ||
| Q4 24 | $-1.7M | $11.5M | ||
| Q3 24 | $-2.9M | $10.9M | ||
| Q2 24 | $-3.5M | $9.5M | ||
| Q1 24 | $-1.8M | $9.6M |
| Q4 25 | 93.2% | — | ||
| Q3 25 | 92.9% | — | ||
| Q2 25 | 92.5% | — | ||
| Q1 25 | 92.2% | — | ||
| Q4 24 | 91.4% | — | ||
| Q3 24 | 90.8% | — | ||
| Q2 24 | 90.0% | — | ||
| Q1 24 | 89.8% | — |
| Q4 25 | 23.5% | 55.8% | ||
| Q3 25 | 11.2% | 57.5% | ||
| Q2 25 | -0.1% | 62.6% | ||
| Q1 25 | -8.9% | 52.6% | ||
| Q4 24 | 18.6% | 51.0% | ||
| Q3 24 | 3.6% | 52.7% | ||
| Q2 24 | -14.3% | 49.3% | ||
| Q1 24 | -8.3% | 50.0% |
| Q4 25 | -5.9% | 43.9% | ||
| Q3 25 | -115.5% | 43.8% | ||
| Q2 25 | -7.8% | 48.0% | ||
| Q1 25 | -15.1% | 39.5% | ||
| Q4 24 | -6.5% | 40.5% | ||
| Q3 24 | -13.2% | 39.4% | ||
| Q2 24 | -17.4% | 37.1% | ||
| Q1 24 | -9.5% | 37.5% |
| Q4 25 | $-0.32 | $1.52 | ||
| Q3 25 | $-3.40 | $1.41 | ||
| Q2 25 | $-0.23 | $1.61 | ||
| Q1 25 | $-0.41 | $1.13 | ||
| Q4 24 | $-0.18 | $1.13 | ||
| Q3 24 | $-0.34 | $1.07 | ||
| Q2 24 | $-0.41 | $0.92 | ||
| Q1 24 | $-0.21 | $0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.6M | — |
| Total DebtLower is stronger | $46.0M | — |
| Stockholders' EquityBook value | $5.9M | $345.6M |
| Total Assets | $72.9M | $3.0B |
| Debt / EquityLower = less leverage | 7.74× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.6M | — | ||
| Q3 25 | $14.9M | — | ||
| Q2 25 | $17.0M | — | ||
| Q1 25 | $20.7M | — | ||
| Q4 24 | $15.9M | — | ||
| Q3 24 | $16.3M | — | ||
| Q2 24 | $6.2M | — | ||
| Q1 24 | $2.8M | — |
| Q4 25 | $46.0M | — | ||
| Q3 25 | $45.1M | — | ||
| Q2 25 | $44.2M | — | ||
| Q1 25 | $43.4M | — | ||
| Q4 24 | $30.7M | $230.8M | ||
| Q3 24 | $30.1M | — | ||
| Q2 24 | $14.4M | — | ||
| Q1 24 | $9.7M | — |
| Q4 25 | $5.9M | $345.6M | ||
| Q3 25 | $6.1M | $334.0M | ||
| Q2 25 | $35.4M | $319.8M | ||
| Q1 25 | $36.7M | $306.1M | ||
| Q4 24 | $39.4M | $295.6M | ||
| Q3 24 | $39.8M | $284.3M | ||
| Q2 24 | $41.7M | $273.4M | ||
| Q1 24 | $43.3M | $266.8M |
| Q4 25 | $72.9M | $3.0B | ||
| Q3 25 | $71.1M | $2.9B | ||
| Q2 25 | $98.8M | $2.9B | ||
| Q1 25 | $96.4M | $2.8B | ||
| Q4 24 | $88.1M | $2.7B | ||
| Q3 24 | $88.5M | $2.6B | ||
| Q2 24 | $73.4M | $2.6B | ||
| Q1 24 | $70.9M | $2.6B |
| Q4 25 | 7.74× | — | ||
| Q3 25 | 7.33× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | 1.18× | — | ||
| Q4 24 | 0.78× | 0.78× | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.22× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.9M | $44.9M |
| Free Cash FlowOCF − Capex | $3.9M | $44.3M |
| FCF MarginFCF / Revenue | 14.0% | 125.7% |
| Capex IntensityCapex / Revenue | 0.3% | 1.6% |
| Cash ConversionOCF / Net Profit | — | 2.90× |
| TTM Free Cash FlowTrailing 4 quarters | $2.2M | $81.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.9M | $44.9M | ||
| Q3 25 | $2.2M | $45.5M | ||
| Q2 25 | $2.7M | $-25.3M | ||
| Q1 25 | $-2.0M | $17.9M | ||
| Q4 24 | $932.0K | $48.0M | ||
| Q3 24 | $2.1M | $17.7M | ||
| Q2 24 | $-1.4M | $-8.4M | ||
| Q1 24 | $-1.6M | $15.8M |
| Q4 25 | $3.9M | $44.3M | ||
| Q3 25 | $1.1M | $45.3M | ||
| Q2 25 | $902.7K | $-25.5M | ||
| Q1 25 | $-3.7M | $17.6M | ||
| Q4 24 | $859.9K | $47.3M | ||
| Q3 24 | $2.0M | $17.5M | ||
| Q2 24 | $-1.5M | $-8.6M | ||
| Q1 24 | $-1.7M | $15.7M |
| Q4 25 | 14.0% | 125.7% | ||
| Q3 25 | 4.2% | 138.1% | ||
| Q2 25 | 3.5% | -74.2% | ||
| Q1 25 | -15.9% | 59.9% | ||
| Q4 24 | 3.3% | 166.5% | ||
| Q3 24 | 9.4% | 63.3% | ||
| Q2 24 | -7.3% | -33.7% | ||
| Q1 24 | -9.0% | 61.4% |
| Q4 25 | 0.3% | 1.6% | ||
| Q3 25 | 4.0% | 0.7% | ||
| Q2 25 | 6.8% | 0.5% | ||
| Q1 25 | 7.4% | 1.0% | ||
| Q4 24 | 0.3% | 2.4% | ||
| Q3 24 | 0.0% | 0.5% | ||
| Q2 24 | 0.3% | 0.5% | ||
| Q1 24 | 0.4% | 0.3% |
| Q4 25 | — | 2.90× | ||
| Q3 25 | — | 3.16× | ||
| Q2 25 | — | -1.54× | ||
| Q1 25 | — | 1.54× | ||
| Q4 24 | — | 4.17× | ||
| Q3 24 | — | 1.62× | ||
| Q2 24 | — | -0.89× | ||
| Q1 24 | — | 1.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
UNTY
Segment breakdown not available.
